Sheena Jonathan

About Sheena Jonathan

Jonathan Sheena is a co-founder of Natera, Inc., a U.S.-listed precision diagnostics company focused on cell-free DNA testing, women’s health, oncology, and organ health. He has served on Natera’s board of directors since 2007. Publicly available company disclosures also show that he served as Natera’s chief technology officer from 2007 until December 2020, making him one of the central figures in the company’s early technical and strategic development. Before Natera, Sheena co-founded PhoneSpots Inc. in 1999, a mobile technology company formerly known as PocketThis Inc. The business served mobile carriers worldwide. During his time there, from June 1999 to December 2007, he held several leadership positions, including vice president of product management and chief technology officer. That experience points to a career built around product strategy, technical leadership, and the commercialization of complex technology platforms. At Natera, Sheena’s influence is tied to the company’s founding phase and its evolution into a major player in genetic testing and precision medicine. He co-founded the business in 2004 with Matthew Rabinowitz and helped shape the technology foundation that supported its expansion into non-invasive prenatal testing, oncology applications, and transplant-related diagnostics. While he is no longer in an operating CTO role, his board service indicates continued involvement in governance and long-term strategic oversight. Because the available public record is relatively concise, it is safest to describe his achievements in broad but accurate terms. He is best characterized as a founder-engineer who combined technical expertise with product leadership and company-building. His most notable contribution appears to be helping establish and guide a diagnostics platform that has become highly relevant in U.S. healthcare. More generally, his career reflects sustained experience in biotechnology-adjacent technology development, executive product management, and board-level stewardship of a public company in the life sciences sector.